​

VYNE Therapeutics Ownership | Who Owns VYNE Therapeutics?

OverviewRevenueFinancialsChart

VYNE Therapeutics Ownership Summary

VYNE Therapeutics is owned by 16.78% institutional investors, 8.28% insiders, and 74.94% retail investors. Staley capital advisers is the largest institutional shareholder, holding 0.09% of VYNE shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.45% of its assets in VYNE Therapeutics shares.

VYNE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockVYNE Therapeutics16.78%8.28%74.94%
SectorHealthcare Stocks 79.82%9.81%10.37%
IndustryBiotech Stocks 63.50%9.87%26.63%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Staley capital advisers36.47K0.09%$122.18K
Ashton thomas private wealth---
Cornerstone planning group---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Staley capital advisers36.47K0.01%$122.18K
Ashton thomas private wealth---
Cornerstone planning group---

Top Buyers

HolderShares% AssetsChange
Staley capital advisers36.47K0.01%-
Cornerstone planning group---2.00
Ashton thomas private wealth---19.00

Top Sellers

HolderShares% AssetsChange
Ashton thomas private wealth---19.00
Cornerstone planning group---2.00
Staley capital advisers36.47K0.01%-

Sold Out

HolderChange
Cornerstone planning group-2.00
Ashton thomas private wealth-19.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025388.57%7,161,7611.37%166.10%2215.79%716.67%
Dec 31, 20241-36,472--1168.22%----
Sep 30, 20241-50.00%36,472-0.05%-1166.04%--100.00%--
Jun 30, 20242-36,4910.05%-68.00%1---
Mar 31, 20242100.00%36,4740.01%-28.75%1---

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF373.32K2.45%-
Vanguard Total Stock Mkt Idx Inv373.32K2.34%-
AlphaCentric LifeSci Healthcare I310.50K2.11%-134.50K
AlphaCentric Life Sciences & Hlthcare I268.49K1.82%-42.02K
Vanguard Institutional Extnd Mkt Idx Tr121.97K0.76%20.65K
Fidelity Extended Market Index70.13K0.46%2.46K
Bridgeway Ultra-Small Company51.96K0.33%15.00K
iShares Micro-Cap ETF33.83K0.22%-
Fidelity Total Market Index21.39K0.14%-
Fidelity Series Total Market Index17.10K0.11%440.00

Recent Insider Transactions

DateNameRoleActivityValue
Jan 15, 2025LEPORE PATRICK G-Buy$43.80K
Nov 15, 2023LEPORE PATRICK G-Buy$50.78K
Mar 20, 2023LEPORE PATRICK G-Buy$49.68K
Mar 20, 2023Harsch Mutya Chief Legal Officer and GCBuy$25.00K
Nov 30, 2021LEPORE PATRICK G-Buy$12.70K

Insider Transactions Trends

DateBuySell
2025 Q11-
2024 Q4--
2024 Q3--
2024 Q2--
2024 Q1--

VYNE Ownership FAQ

Who Owns VYNE Therapeutics?

VYNE Therapeutics shareholders are primarily institutional investors at 16.78%, followed by 8.28% insiders and 74.94% retail investors. The average institutional ownership in VYNE Therapeutics's industry, Biotech Stocks , is 63.50%, which VYNE Therapeutics falls below.

Does Blackrock own VYNE Therapeutics?

BlackRock is not among the top 10 institutional shareholders of VYNE Therapeutics.

Who is VYNE Therapeutics’s biggest shareholder by percentage of total assets invested?

Staley capital advisers is VYNE Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.01% of its assets in 36.47K VYNE Therapeutics shares, valued at 122.18K$.

Who is the top mutual fund holder of VYNE Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of VYNE Therapeutics shares, with 2.45% of its total shares outstanding invested in 373.32K VYNE Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools